Medical devices safe from HTA in Germany – for now
This article was originally published in Clinica
Executive Summary
The German health service currently stands on the brink of a health technology assessment revolution. In accordance with the last Healthcare Reform Act of April 2007, from 1 September 2009 innovative pharmaceuticals that are entering the German market and require reimbursement will for the first time be subject to a cost/benefit evaluation. In essence, this does not appear to affect the medical devices industry, but the industry association, BVMed, is by no means being complacent.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.